|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
|
EP2451461A4
(en)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
WO2014010250A1
(en)
|
2012-07-13 |
2014-01-16 |
Chiralgen, Ltd. |
Asymmetric auxiliary group
|
|
DK2872147T3
(da)
|
2012-07-13 |
2023-02-20 |
Wave Life Sciences Ltd |
Fremgangsmåde til fremstilling af kirale oligonukleotider
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
AU2015367378A1
(en)
|
2014-12-17 |
2017-06-15 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
CN117965536A
(zh)
|
2015-07-22 |
2024-05-03 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
MA43822A
(fr)
|
2016-03-13 |
2018-11-28 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
WO2018041973A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
WO2018098264A1
(en)
|
2016-11-23 |
2018-05-31 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
NZ755416A
(en)
|
2016-12-19 |
2023-05-26 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
ES3051834T3
(en)
|
2016-12-19 |
2025-12-30 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018237194A1
(en)
|
2017-06-21 |
2018-12-27 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
AU2018316159A1
(en)
|
2017-08-08 |
2020-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CN111108096A
(zh)
|
2017-09-18 |
2020-05-05 |
波涛生命科学有限公司 |
寡核苷酸制备技术
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
SG11202002517RA
(en)
*
|
2017-09-22 |
2020-04-29 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
US11559527B2
(en)
|
2017-12-20 |
2023-01-24 |
Lunella Biotech, Inc. |
Targeting mitochondrial fission through mDIVI-1 derivatives
|
|
JP2021521140A
(ja)
|
2018-04-12 |
2021-08-26 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
CA3098623A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
JP7583712B2
(ja)
*
|
2018-05-30 |
2024-11-14 |
ノバルティス アーゲー |
脂質修飾された核酸化合物および方法
|
|
EP4219717A3
(en)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
BR112021011018A2
(pt)
|
2018-12-13 |
2021-08-31 |
Sarepta Therapeutics, Inc. |
Conjugados de oligômero para exon skipping para distrofia muscular
|
|
WO2020132263A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Aegis Therapeutics, Inc. |
Compositions, devices, and methods for the treatment of overdose and reward-based disorders
|
|
CN109799216B
(zh)
*
|
2018-12-29 |
2021-11-12 |
佛山科学技术学院 |
一种基于吲哚箐绿纳米的荧光oct双模成像方法和装置
|
|
WO2020158636A1
(ja)
*
|
2019-01-29 |
2020-08-06 |
国立大学法人東京大学 |
核酸等を細胞内へ導入する方法
|
|
AU2020241559A1
(en)
|
2019-03-20 |
2021-11-11 |
Wave Life Sciences Ltd. |
Technologies useful for oligonucleotide preparation
|
|
CN109870583B
(zh)
*
|
2019-04-15 |
2020-03-06 |
德阳市人民医院 |
急性胰腺炎相关的代谢物及其应用
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
JP7186442B2
(ja)
*
|
2019-04-22 |
2022-12-09 |
国立研究開発法人産業技術総合研究所 |
新規スクアレン誘導体および抗炎症剤
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
MX2021012981A
(es)
|
2019-04-25 |
2022-01-18 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotido y metodos de uso de las mismas.
|
|
KR20220011697A
(ko)
*
|
2019-05-22 |
2022-01-28 |
바이오비에 아이앤씨. |
테를리프레신 제형
|
|
JP7627495B2
(ja)
|
2019-07-12 |
2025-02-06 |
学校法人東海大学 |
ＤＵＸ４ ｐｒｅ－ｍＲＮＡのスプライシングを変化させるアンチセンスオリゴヌクレオチド
|
|
CN110527698B
(zh)
*
|
2019-08-23 |
2021-10-01 |
温氏食品集团股份有限公司 |
一种利用小分子化合物提高基因组定点插入效率的方法
|
|
JP2023503644A
(ja)
*
|
2019-11-27 |
2023-01-31 |
ディー・ティー・エックス・ファーマ・インコーポレイテッド |
デュシェンヌ型筋ジストロフィーの治療のための化合物および方法
|
|
CN111063870B
(zh)
*
|
2019-11-27 |
2021-09-24 |
深圳先进技术研究院 |
纳米材料及其制备方法、电极和二次电池
|
|
CN111012788B
(zh)
*
|
2019-12-12 |
2021-01-15 |
武汉职业技术学院 |
硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
|
|
CN111055603B
(zh)
*
|
2019-12-31 |
2021-11-05 |
安徽省粤隆印刷科技有限公司 |
一种防止残剩油墨过度乳化和形成残渣的包装盒印刷工艺
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
AU2021230473A1
(en)
*
|
2020-03-01 |
2022-09-22 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
CN111358955B
(zh)
*
|
2020-04-01 |
2023-05-02 |
重庆理工大学 |
一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用
|
|
CN111249298B
(zh)
*
|
2020-04-08 |
2021-03-12 |
曲阜师范大学 |
一种含有马杜霉素和顺铂的抗癌药物组合物
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
IT202000012577A1
(it)
*
|
2020-05-27 |
2021-11-27 |
Univ Degli Studi Roma La Sapienza |
Composizione farmaceutica per l’inibizione chimica di tgs1 come trattamento terapeutico per le telomeropatie
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
CN111789859A
(zh)
*
|
2020-07-20 |
2020-10-20 |
中国人民解放军海军军医大学 |
地塞米松在制备预防或缓解水母蜇伤药物中的应用
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2022069511A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Biomarin Technologies B.V. |
Antisense oligonucleotides targeting the exon 51 of dystrophin gene
|
|
EP3978608A1
(en)
*
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
|
|
CN115216474B
(zh)
*
|
2021-04-15 |
2025-09-30 |
武汉大学 |
促进pd-l1外显子3跳跃的反义寡核苷酸及其应用
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
CN113520995B
(zh)
*
|
2021-08-16 |
2023-03-10 |
海南鑫开源医药科技有限公司 |
一种离子敏感型眼用原位凝胶、其制备方法及应用
|
|
IL311507A
(en)
*
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
EP4401792A4
(en)
|
2021-09-16 |
2025-12-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
US20240425864A1
(en)
|
2021-09-30 |
2024-12-26 |
Sarepta Therapeutics, Inc. |
Antisense oligonucleotides having one or more abasic units
|
|
EP4479535A1
(en)
|
2022-02-14 |
2024-12-25 |
ProQR Therapeutics II B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4555085A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
EP4590311A2
(en)
|
2022-09-21 |
2025-07-30 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
KR20250113455A
(ko)
|
2022-11-24 |
2025-07-25 |
프로큐알 테라퓨틱스 Ⅱ 비.브이. |
유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
WO2024121373A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
WO2024175550A1
(en)
|
2023-02-20 |
2024-08-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
US12396981B2
(en)
|
2023-03-09 |
2025-08-26 |
William Shulman |
Methods of using DMT
|
|
JP2026510408A
(ja)
|
2023-03-24 |
2026-04-02 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
神経障害の処置のためのアンチセンスオリゴヌクレオチド
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
EP4688143A1
(en)
|
2023-03-27 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
EP4702144A1
(en)
|
2023-04-27 |
2026-03-04 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of chronic kidney disease
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
CN116754689A
(zh)
*
|
2023-07-27 |
2023-09-15 |
苏州和合医学检验有限公司 |
一种高效液相色谱串联质谱法检测5种药物的方法及应用
|
|
CN117099681B
(zh)
*
|
2023-08-28 |
2024-07-05 |
南京农业大学 |
一种利用紫杉醇加倍玉米单倍体的方法
|
|
EP4774393A1
(en)
|
2023-09-07 |
2026-07-15 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025085810A2
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of centronuclear myopathies
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
AU2024379264A1
(en)
|
2023-11-16 |
2026-05-14 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
AU2024402199A1
(en)
|
2023-12-20 |
2026-07-16 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025213142A2
(en)
*
|
2024-04-05 |
2025-10-09 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
CN119015397B
(zh)
*
|
2024-08-20 |
2025-04-18 |
广州医科大学附属中医医院(广州市中医中药研究所、广州市中医医院、广州中医药大学附属广州中医医院、广州市针灸医院) |
一种抑制人前列腺癌细胞增殖的白僵菌素组合物及其制备方法
|
|
WO2026050243A1
(en)
|
2024-08-26 |
2026-03-05 |
Korro Bio, Inc. |
Galnac conjugated oligonucleotides for rna editing
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2026093339A1
(en)
|
2024-10-29 |
2026-05-07 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
|
|
WO2026122478A1
(en)
|
2024-12-02 |
2026-06-11 |
Korro Bio, Inc. |
Extrahepatic delivery formulations and methods
|
|
WO2026136663A1
(en)
|
2024-12-18 |
2026-06-25 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|